Dermapharm Holding Se · XETR:DMP
Dermapharm — Q1 2023 Earnings Presentation
19 slides from Dermapharm's earnings presentation, May 15, 2023
Slide 1: Interim Statement Q1 2023
Dermapharm Holding se INTERIM STATEMENT Q1 2023
Slide 2: Consolidated results at a glance
DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 2 Consolidated results at a glance Q1 2023 Q1 2022 Revenue EUR million 319.1 231.6 Adjusted EBITDA* EUR million 105.8 75.1 Adjusted EBITDA margin* % 33.2 32.4 Unadjusted EBITDA EUR million 98.0 71.3 Unadjusted EBITDA margin % 30.7 30.8 Operating
Slide 3: Share Information
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 3 SHARE INFORMATION Dermapharm Holding SE share (Xetra) General information EUR German Securitie
Slide 4: Key share figures Q1 2023 and Financial Calendar 2023
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 4 Key share figures Q1 2023 Financial Calendar 2023 Share information Q1 2023 (XETRA) Annual Gen
Slide 5: Report on economic position: Course of business
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 5 REPORT ON ECONOMIC POSITION Branded pharmaceuticals and other healthcare products 1. Course of
Slide 6: Parallel import business
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 6 Parallel import business Revenue for the parallel import business rose by 9.9% to EUR 66.4 mil
Slide 7: Revenue and earnings performance
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 7 2. Revenue and earnings performance Revenue trend Yearly and quarterly comparison of revenue t
Slide 8: Earnings before interest, tax, depreciation and amortisation (EBITDA)
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 8 Earnings before interest, tax, depreciation and amortisation (EBITDA) Yearly and quarterly com
Slide 9: Performance of the segments
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 9 Performance of the segments Quarter-on-quarter revenue trend by segment Quarter-on-quarter EBI
Slide 10: Report on expected developments
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 10 Report on expected developments The Group’s performance in Q1 2023 was in line with our assum
Slide 11: Interim consolidated financial statements as at 31 March 2023
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 11 INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 MARCH 2023 Rounding differences may arise
Slide 12: Equity and liabilities
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 12 Equity and liabilities EUR thousand 31 March 2023 31 December 2022 Equity Issued capital 53,8
Slide 13: Condensed statement of comprehensive income
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 13 Condensed statement of comprehensive income EUR thousand Q1 2023 Q1 2022 Revenue 319,118 231,
Slide 14: Comprehensive income and earnings per share
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 14 EUR thousand Q1 2023 Q1 2022 Other comprehensive income not reclassified to profit or loss in
Slide 15: Condensed statement of cash flows
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 15 Condensed statement of cash flows EUR thousand Q1 2023 Q1 2022 Earnings before taxes 69,792 5
Slide 16: Cash flows from financing activities
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 16 EUR thousand Q1 2023 Q1 2022 Proceeds from borrowings 650,000 20,000 Repayments of borrowings
Slide 17: Segment reporting
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 17 Segment reporting Branded pharmaceuticals and Reconciliation/ other healthcare products Herba
Slide 18: Imprint
To the shareholders / Report on economic position / Report on expected developments / Interim consolidated financial statements / Further information DERM APH A RM HOLD IN G SE INTERIM STATEM ENT Q1 2023 18 IMPRINT Publisher Concept, editing, layout & typesetting Dermapharm Holding SE SPARKS CONSULT
Slide 19: Dermapharm Holding SE contact details
Dermapharm Holding SE Lil-Dagover-Ring 7 82031 Grünwald Germany Tel.: +49 (89) 6 41 86 – 0 E-Mail: ir@dermapharm.com https://ir.dermapharm.de